Information  X 
Enter a valid email address

FastForward Inn Ltd (FFWD)

  Print   

Thursday 18 February, 2021

FastForward Inn Ltd

Investee Company Update: Little Green Pharma Ltd

RNS Number : 5764P
FastForward Innovations Limited
18 February 2021
 

FastForward Innovations Ltd / AIM: FFWD / Sector: Closed End Investments

18 February 2021

FastForward Innovations Ltd

("FastForward", "FFWD" or the "Company")

 

Investee Company Update: Little Green Pharma Ltd

 

FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, is pleased to note that Little Green Pharma Ltd ('LGP') has today announced that it will be exclusively supplying medicinal cannabis oil products to enrolled patients as well as providing funding for study costs for the QUality of life Evaluation STudy ("The QUEST Initiative"). The QUEST Initiative, which is being conducted by researchers at the University of Sydney, aims to be one of the world's largest longitudinal studies investigating the quality of life and health economics on patients with chronic disease prescribed medicinal cannabis. FastForward has a 0.9% interest in the issued stock of LGP.

Ed McDermott, CEO of FastForward Innovations, commented: "Little Green Pharma is one of our newest investments in the medical cannabis space and we are delighted that it is already delivering such strong newsflow. The QUEST Initiative aims to have at least 2,100 patients by 30 June 2021, which is a very significant number, and it is excellent to hear that Little Green Pharma is involved with the exclusive supply of medical cannabis oil products as well as providing funding for study costs. We look forward to providing updates as the study progresses."

 

The announcement is set out below without material changes or adjustments other than for the inclusion of links and can be viewed in full on LGP's website via the following link: https://investor.littlegreenpharma.com/site/PDF/9f6a7d18-b9ad-4d67-b892-c630bf7f9727/LargeScaleCannabisStudyLaunched

 

LARGE SCALE CANNABIS STUDY LAUNCHED

 18 FEBRUARY 2021

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") wishes to advise of the media release issued today by the University of Sydney relating to the QUality of life Evaluation STudy ("The QUEST Initiative").

The QUEST Initiative aims to be one of the world's largest longitudinal studies investigating the quality of life and health economics on patients with chronic disease prescribed medicinal cannabis.

LGP will exclusively supply medicinal cannabis oil products to enrolled patients as well as providing funding for study costs.

The study, conducted by researchers at the University of Sydney, is for a two-year period and aims to recruit at least 2,100 patients by 30 June 2021. It also has the potential to be extended internationally.

Please see the Little Green Pharma announcement for details of the study which can be found in an attached media release from the University of Sydney.

ASX ANNOUNCEMENT LGP TO EXCLUSIVELY SUPPLY CANNABIS MEDICINES TO WIDE-RANGING QUALITY OF LIFE STUDY ENDS FOR MORE INFORMATION, PLEASE CONTACT:

Alistair Warren

Company Secretary

Little Green Pharma

E: [email protected]  

M: +61 8 6280 0050

Fleta Solomon

Managing Director

Little Green Pharma

E: [email protected]  

M: +41 782 260 200

 

About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility and manufacturing facility in Western Australia for the production of its own-branded range of GMP-grade medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

*** ENDS***

 

For further information on the Company please visit www.fstfwd.co   or contact:

Ed McDermott / Lance de Jersey

FastForward Innovations Ltd

Email: [email protected]  

 

James Biddle / Roland Cornish

Beaumont Cornish Limited,

Nomad

 

Tel: +44 (0) 207 628 3396

 

Isabella Pierre / Damon Heath

Shard Capital Partners LLP

 

T: +44 (0)20 7186 9927

Isabel de Salis / Beth Melluish

St Brides Partners Ltd,

Financial PR

 

Email: [email protected]

 

Notes

FastForward Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFZGMZLRDGMZG

a d v e r t i s e m e n t